drugset
drugset / Trial / NCT04633733

The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus

NCT04633733 ↗

Phase 1 Unknown 24 enrolled Hanlim Pharm. Co., Ltd.
NaSequentialOpen-labelOther

Summary

This study aims to evaluate the pharmacokinetic interaction between HL237 and tacrolimus in healthy male subjects.

Timeline

Start
2020-08-22
Primary completion
2020-09-24
Completion
2021-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HL237 Unknown 400 mg Oral
Subject Tacrolimus Small molecule 5 mg Oral

Indications

No indication recorded.